Responding to Structural Industry Changes: A Technological Evolution Perspective, Industrial and Corporate Change, vol.6, issue.1, pp.183-202, 1997. ,
DOI : 10.1093/icc/6.1.183
The Market Evolution and Sales Takeoff of Product Innovations, Management Science, vol.48, issue.8, pp.1024-1041, 2002. ,
DOI : 10.1287/mnsc.48.8.1024.167
Technology and Industry Evolution, Handbook of Technology and Innovation Management, 2008. ,
Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry, Technovation, vol.31, issue.2-3, pp.105-117, 2011. ,
DOI : 10.1016/j.technovation.2010.11.001
The future of drug discovery and development: Shifting emphasis towards personalized medicine, Technological Forecasting and Social Change, vol.77, issue.2, pp.203-217, 2010. ,
DOI : 10.1016/j.techfore.2009.09.005
URL : https://hal.archives-ouvertes.fr/hal-00749148
Alliance Activity as a Dynamic Capability in the Face of a Discontinuous Technological Change. Organization Science Forthcoming, 2010. ,
Technological Discontinuities and Dominant Designs: A Cyclical Model of Technological Change, Administrative Science Quarterly, vol.35, issue.4, pp.604-633, 1990. ,
DOI : 10.2307/2393511
The changing technology of technological change: general and abstract knowledge and the division of innovative labour, Research Policy, vol.23, issue.5, pp.523-532, 1994. ,
DOI : 10.1016/0048-7333(94)01003-X
Editorial, Long Range Planning, vol.43, issue.2-3, pp.143-145, 2010. ,
DOI : 10.1016/j.lrp.2010.03.002
Process Management and Technological Innovation: A Longitudinal Study of the Photography and Paint Industries, Administrative Science Quarterly, vol.47, issue.4, p.676, 2002. ,
DOI : 10.2307/3094913
Securities Analysts and Incumbent Response to Radical Technological Change: Evidence from Digital Photography and Internet Telephony, Organization Science, vol.21, issue.1, pp.42-62, 2010. ,
DOI : 10.1287/orsc.1080.0395
The dominant logic: Retrospective and extension, Strategic Management Journal, vol.10, issue.1, pp.5-14, 1995. ,
DOI : 10.1002/smj.4250160104
Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis, Technovation, vol.31, issue.1, pp.22-33, 2011. ,
DOI : 10.1016/j.technovation.2010.03.002
Bargaining power in alliance governance negotiations: evidence from the biotechnology industry, Technovation, vol.30, issue.5-6, pp.367-375, 2010. ,
DOI : 10.1016/j.technovation.2010.01.003
Four scenarios for the future of the pharmaceutical industry, Technology Analysis & Strategic Management, vol.21, issue.2, pp.195-212, 2009. ,
DOI : 10.1080/09537320802625280
Des nanobiotechnologies à la nanomédecine du futur, BioFutur, vol.265, pp.57-62, 2006. ,
From Strategy to Business Models and onto Tactics, Long Range Planning, vol.43, issue.2-3, pp.2-3, 2010. ,
DOI : 10.1016/j.lrp.2010.01.004
Anticipating converging industries using publicly available data, Technological Forecasting and Social Change, vol.77, issue.3, pp.385-395, 2010. ,
DOI : 10.1016/j.techfore.2009.10.002
Global Pharmaceuticals, Biotechnology & Life Sciences Industry Profile: Reference, vol.code, pp.199-2357, 2010. ,
Abstract:, Business Ethics Quarterly, vol.15, issue.04, pp.549-575, 2005. ,
DOI : 10.5840/beq200515444
Business Model Evolution: In Search of Dynamic Consistency, Long Range Planning, vol.43, issue.2-3, pp.2-3, 2010. ,
DOI : 10.1016/j.lrp.2010.02.004
URL : https://hal.archives-ouvertes.fr/hal-00572915
ORCHESTRATING INNOVATION NETWORKS., Academy of Management Review, vol.31, issue.3, pp.659-669, 2006. ,
DOI : 10.5465/AMR.2006.21318923
The cost of biopharmaceutical R&D: is biotech different?, Managerial and Decision Economics, vol.13, issue.4-5, pp.469-479, 2007. ,
DOI : 10.1002/mde.1360
The price of innovation: new estimates of drug development costs, Journal of Health Economics, vol.22, issue.2, pp.151-185, 2003. ,
DOI : 10.1016/S0167-6296(02)00126-1
Embedding Strategic Agility, Long Range Planning, vol.43, issue.2-3, pp.2-3, 2010. ,
DOI : 10.1016/j.lrp.2009.07.006
Do science and money go together? The case of the French biotech industry, Strategic Management Journal, vol.88, issue.1, pp.1281-1299, 2008. ,
DOI : 10.1002/smj.707
URL : https://hal.archives-ouvertes.fr/hal-00422650
Biotechnology: Its origins, organization, and outputs, Research Policy, vol.36, issue.4, pp.433-437, 2007. ,
DOI : 10.1016/j.respol.2007.04.001
Building theories from case study research, Academy of Management Review, vol.14, issue.4, pp.532-550, 1989. ,
THEORY BUILDING FROM CASES: OPPORTUNITIES AND CHALLENGES., Academy of Management Journal, vol.50, issue.1, pp.25-32, 2007. ,
DOI : 10.5465/AMJ.2007.24160888
Organizational Routines as a Source of Continuous Change, Organization Science, vol.11, issue.6, pp.611-629, 2000. ,
DOI : 10.1287/orsc.11.6.611.12529
Business models and investment trends in the biotechnology industry in Europe, Journal of Commercial Biotechnology, vol.8, issue.3, pp.191-199, 2002. ,
DOI : 10.5912/jcb431
Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation, Business History Review, vol.37, issue.02, 1998. ,
DOI : 10.1016/S0048-7333(97)00017-6
Business-Model Innovation: General Purpose Technologies and their Implications for Industry Structure, Long Range Planning, vol.43, issue.2-3, pp.2-3, 2010. ,
DOI : 10.1016/j.lrp.2009.07.009
Organizing Pharmaceutical Innovation: From Science-based Knowledge Creators to Drug-oriented Knowledge Brokers, Creativity and Innovation Management, vol.24, issue.3, pp.233-245, 2005. ,
DOI : 10.1002/(SICI)1097-0266(199907)20:7<637::AID-SMJ42>3.3.CO;2-Q
The Discovery of Grounded Theory; Strategies for Qualitative Research, Nursing Research, vol.17, issue.4, 1967. ,
DOI : 10.1097/00006199-196807000-00014
UNBUNDLING THE STRUCTURE OF INERTIA: RESOURCE VERSUS ROUTINE RIGIDITY., Academy of Management Journal, vol.48, issue.5, pp.741-763, 1995. ,
DOI : 10.5465/AMJ.2005.18803920
Personalized medicine: revolutionizing drug discovery and patient care, Trends in Biotechnology, vol.19, issue.12, pp.491-496, 2001. ,
DOI : 10.1016/S0167-7799(01)01814-5
Strategic innovation: a conceptual Road Map Business Horizons, pp.44-48, 2001. ,
Structure and Strategy in Grocery Retailing: A Sociometric Approach, The Journal of Industrial Economics, vol.33, issue.3, pp.339-347, 1985. ,
DOI : 10.2307/2098541
SUSTAINABILITY INNOVATION CUBE ??? A FRAMEWORK TO EVALUATE SUSTAINABILITY-ORIENTED INNOVATIONS, International Journal of Innovation Management, vol.13, issue.04, pp.683-713, 2009. ,
DOI : 10.1142/S1363919609002479
Large Firms, Small Firms and the Governance of Flexible Specialization: Baden- Württemberg and the Socialization of Risk, Country Competitiveness: Technology and the Organizing of Work, 1993. ,
The performance of incumbent firms in the face of radical technological innovation, Academy of Management Review, vol.28, issue.2, p.257, 2003. ,
Emerging Challenges and Opportunities in Drug Registration and Regulation in Developing Countries, 2004. ,
Cognitive Inertia in a Turbulent Market: the Case of UK Residential Estate Agents, Journal of Management Studies, vol.34, issue.6, pp.921-945, 1997. ,
DOI : 10.1111/1467-6486.00078
Confronting Strategic Inertia in a Top Management Team: Learning from Failure, Organization Studies, vol.8, issue.6, pp.947-977, 2002. ,
DOI : 10.1177/0170840602236014
The myth of the biotech revolution: An assessment of technological, clinical and organisational change, Research Policy, vol.36, issue.4, pp.566-589, 2007. ,
DOI : 10.1016/j.respol.2007.02.013
Business models in the bioinformatics industry, 2009. ,
Industry Life Cycles, Industrial and Corporate Change, vol.6, issue.1, pp.145-181, 1997. ,
DOI : 10.1093/icc/6.1.145
The Structure of Scientific Revolutions, 1962. ,
The External Sourcing of Technological Knowledge by US Pharmaceutical Companies: Strategic Goals and Inter???organizational Relationships, Industry & Innovation, vol.40, issue.1, pp.5-25, 2007. ,
DOI : 10.1080/00343400220122070
Managing Drug Discovery Alliances for Success Research Technology Management, pp.42-50, 2005. ,
Demythologizing the high costs of pharmaceutical research, BioSocieties, vol.276, issue.1, pp.34-50, 2011. ,
DOI : 10.1001/jama.1996.03540150055031
Six Issues in Pharmaceuticals. Institute of Economic Affairs, pp.33-38, 2006. ,
Three eras of technology foresight, Technovation, vol.31, issue.2-3, pp.69-76, 2011. ,
DOI : 10.1016/j.technovation.2010.10.001
Integrating innovation and learning curve theory: an enabler for moving nanotechnologies and other emerging process technologies into production, R and D Management, vol.44, issue.7, pp.517-526, 2004. ,
DOI : 10.1016/0160-791X(85)90022-3
Developing consensus on firm competencies and capabilities., Academy of Management Perspectives, vol.10, issue.3, pp.40-51, 1996. ,
DOI : 10.5465/AME.1996.9704111473
Living with 'Dinosaurs': What the case of genomics tells us about the role of New Technology Based Firms in the pharmaceutical industry. Working paper, 2010. ,
The global health complex, BioSocieties, vol.372, issue.3, pp.1-9, 2011. ,
DOI : 10.1016/S0140-6736(08)61485-3
Qualitative Data Analysis: An Expanded Sourcebook, 1994. ,
US and European regulatory initiatives to improve R&D performance, Expert Opinion on Drug Discovery, vol.40, issue.1, pp.11-14, 2006. ,
DOI : 10.1517/17460441.1.1.11
Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms, Technology Analysis & Strategic Management, vol.19, issue.3, pp.279-301, 2007. ,
DOI : 10.1080/09537320701281540
The entrepreneur's business model: toward a unified perspective, Journal of Business Research, vol.58, issue.6, pp.726-735, 2005. ,
DOI : 10.1016/j.jbusres.2003.11.001
The Birth of the 'Kodak Moment': Institutional Entrepreneurship and the Adoption of New Technologies, Organization Studies, vol.42, issue.11, pp.1665-1687, 2005. ,
DOI : 10.1177/0170840605056395
Characteristics of the Italian biotechnology industry and new business models: the initial results of an empirical study, Technovation, vol.25, issue.8, pp.841-855, 2005. ,
DOI : 10.1016/j.technovation.2004.02.002
Sectoral patterns of technical change: Towards a taxonomy and a theory, Research Policy, vol.13, issue.6, pp.343-375, 1984. ,
DOI : 10.1016/0048-7333(84)90018-0
Longitudinal Field Research on Change: Theory and Practice, Organization Science, vol.1, issue.3, 1990. ,
DOI : 10.1287/orsc.1.3.267
A framework for mapping industrial emergence, Technological Forecasting and Social Change, vol.78, issue.2, pp.217-230, 2011. ,
DOI : 10.1016/j.techfore.2010.06.018
Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience, Technovation, vol.22, issue.2, pp.81-90, 2002. ,
DOI : 10.1016/S0166-4972(01)00081-5
Can science be a business? Lessons from, Biotech Harvard Business Review, vol.84, issue.10, pp.114-125, 2006. ,
Transforming the critique of Big Pharma, BioSocieties, vol.25, issue.9, pp.106-118, 2011. ,
DOI : 10.1146/annurev.anthro.25.1.153
Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology, Administrative Science Quarterly, vol.41, issue.1, pp.116-145, 1996. ,
DOI : 10.2307/2393988
The Blinders of Dominant Logic, Long Range Planning, vol.37, issue.2, pp.171-179, 2004. ,
DOI : 10.1016/j.lrp.2004.01.010
The dominant logic: A new linkage between diversity and performance, Strategic Management Journal, vol.185, issue.6, pp.485-501, 1986. ,
DOI : 10.1002/smj.4250070602
America's Other Drug Problem, The New Republic, issue.16, pp.27-41, 2002. ,
Technological Discontinuities and the Nature of Competition, Technology Analysis & Strategic Management, vol.1, issue.2, 2000. ,
DOI : 10.1093/icc/1.2.327
Complementary assets, strategic alliances, and the incumbent???s advantage: an empirical study of industry and firm effects in the biopharmaceutical industry, Research Policy, vol.30, issue.8, pp.1235-1251, 2001. ,
DOI : 10.1016/S0048-7333(00)00142-6
Incumbent's advantage through exploiting complementary assets via interfirm cooperation, Strategic Management Journal, vol.10, issue.6-7, pp.687-699, 2001. ,
DOI : 10.1002/smj.180
Technological discontinuities and interfirm cooperation: what determines a startup's attractiveness as alliance partner?, IEEE Transactions on Engineering Management, vol.49, issue.4, p.388, 2002. ,
DOI : 10.1109/TEM.2002.806725
Technological Discontinuities and Complementary Assets: A Longitudinal Study of Industry and Firm Performance, Organization Science, vol.16, issue.1, pp.52-70, 2005. ,
DOI : 10.1287/orsc.1040.0100
Downstream and into deep biology: Evolving business models in 'top tier' genomics companies, Journal of Commercial Biotechnology, vol.12, issue.2, pp.86-98, 2006. ,
DOI : 10.5912/jcb154
Biologie Systémique: standards et modèles, 2007. ,
From Recipe to Dinner: Business Model Portfolios in the European Biopharmaceutical Industry, Long Range Planning, vol.43, issue.2-3, pp.2-3 ,
DOI : 10.1016/j.lrp.2010.02.001
Orchestrating networks in the biopharmaceutical industry: small hub firms can do it, Production Planning & Control, vol.40, issue.2, pp.218-228 ,
DOI : 10.1016/j.respol.2007.02.015
URL : https://hal.archives-ouvertes.fr/hal-00468340
Constructing Markets and Shaping Boundaries: Entrepreneurial Power in Nascent Fields, Academy of Management Journal, vol.52, issue.4, pp.643-671, 2009. ,
DOI : 10.5465/AMJ.2009.43669892
Business Model Innovation through Trial-and-Error Learning, Long Range Planning, vol.43, issue.2-3, pp.383-407, 2010. ,
DOI : 10.1016/j.lrp.2010.02.003
Cooperation in R&D in the pharmaceutical industry ??? The network as an organizational innovation governing technological innovation, Technovation, vol.18, issue.1, pp.13-23, 1998. ,
DOI : 10.1016/S0166-4972(97)00107-7
The regional world: Territorial development in a global economy, 1997. ,
Spontaneous vs. policy-driven: The origin and evolution of the biotechnology cluster, Technological Forecasting and Social Change, vol.76, issue.5, pp.608-619, 2009. ,
DOI : 10.1016/j.techfore.2008.08.008
Organizational Linkages for Surviving Technological Change: Complementary Assets, Middle Management, and Ambidexterity, Organization Science, vol.20, issue.4, pp.718-739, 2009. ,
DOI : 10.1287/orsc.1090.0429
Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy, Research Policy, vol.15, issue.6, pp.285-305, 1986. ,
DOI : 10.1016/0048-7333(86)90027-2
Business Models, Business Strategy and Innovation, Long Range Planning, vol.43, issue.2-3, pp.172-174, 2010. ,
DOI : 10.1016/j.lrp.2009.07.003
Strategic Patenting in Biotechnology, Technology Analysis & Strategic Management, vol.16, issue.4, pp.529-538, 2004. ,
DOI : 10.1080/0953732042000295829
Organizational Determinants of Technological Change: Toward a Sociology of Technological Evolution, Research in Organizational Behavior, vol.14, pp.311-347, 1992. ,
A dynamic model of process and product innovation, Omega, vol.3, issue.6, pp.639-656, 1975. ,
DOI : 10.1016/0305-0483(75)90068-7
Does a clustered location matter for high-technology companies' performance? The case of biotechnology in the Netherlands, Technological Forecasting and Social Change, vol.74, issue.9, pp.1681-1696, 2007. ,
DOI : 10.1016/j.techfore.2006.10.009
Exploring the Link between Dominant Logic and Company Performance, Creativity and Innovation Management, vol.9, issue.2, pp.82-93, 2000. ,
DOI : 10.1111/1467-8691.00160
Entrepreneurs' opportunities and technology based markets, Technological Entrepreneurship, pp.17-30, 2002. ,
Technology management and collaboration profile: virtual companies and industrial platforms in the high-tech biotechnology industries, R and D Management, vol.31, issue.1, pp.91-100, 2001. ,
DOI : 10.1111/1467-9310.00199
Schumpeterian competition in alternative technological regimes, Journal of Economic Behavior & Organization, vol.5, issue.3-4, pp.287-320, 1984. ,
DOI : 10.1016/0167-2681(84)90004-0
Working Party on the Information Economy, Digital Broadband Content: Music, OECD Report, 2004. ,
IAMOT and Education: Defining a Technology and Innovation Management (TIM) Body-of-Knowledge (BoK) for graduate education (TIM BoK), Technovation, vol.30, issue.7-8, 2010. ,
DOI : 10.1016/j.technovation.2010.03.007